title: EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.
abstract: By means of an unbiased, automated fluorescence microscopy-based screen, we identified the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib as potent enhancers of the differentiation of HL-60 acute myeloid leukemia (AML) cells exposed to suboptimal concentrations of vitamin A (all-trans retinoic acid, ATRA) or vitamin D (1α,25-hydroxycholecalciferol, VD). Erlotinib and gefitinib alone did not promote differentiation, yet stimulated the acquisition of morphological and biochemical maturation markers (including the expression of CD11b and CD14 as well as increased NADPH oxidase activity) when combined with either ATRA or VD. Moreover, the combination of erlotinib and ATRA or VD synergistically induced all the processes that are normally linked to terminal hematopoietic differentiation, namely, a delayed proliferation arrest in the G0/G1 phase of the cell cycle, cellular senescence, and apoptosis. Erlotinib potently inhibited the (auto)phosphorylation of mitogen-activated protein kinase 14 (MAPK14, best known as p38(MAPK)) and SRC family kinases (SFKs). If combined with the administration of ATRA or VD, the inhibition of p38(MAPK) or SFKs with specific pharmacological agents mimicked the pro-differentiation activity of erlotinib. These data were obtained with 2 distinct AML cell lines (HL-60 and MOLM-13 cells) and could be confirmed on primary leukemic blasts isolated from the circulation of AML patients. Altogether, these findings point to a new regimen for the treatment of AML, in which naturally occurring pro-differentiation agents (ATRA or VD) may be combined with EGFR inhibitors.
authors: INSERM; U848; Villejuif, France; Gustave Roussy; Villejuif, France; Université Paris Sud/Paris XI; Le Kremlin Bicêtre, France; Hôpital Robert Debré; AP-HP; Paris, France.
authors: Elodie
authors: E
authors: Lainey
authors: Alice
authors: A
authors: Wolfromm
authors: Abdul Qader
authors: AQ
authors: Sukkurwala
authors: Jean-Baptiste
authors: JB
authors: Micol
authors: Pierre
authors: P
authors: Fenaux
authors: Lorenzo
authors: L
authors: Galluzzi
authors: Oliver
authors: O
authors: Kepp
authors: Guido
authors: G
authors: Kroemer
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D039481:CD11b Antigen / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects*; D002762:Cholecalciferol / Q000494:pharmacology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D018922:HL-60 Cells; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000473:pathology; D048308:Mitogen-Activated Protein Kinase 14 / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D019061:src-Family Kinases / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D039481:CD11b Antigen; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D002762:Cholecalciferol; D014212:Tretinoin; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D019061:src-Family Kinases; D048308:Mitogen-Activated Protein Kinase 14
keywords: BCR-ABL; PML-RARα; cancer; dasatinib; imatinib; monocyte-specific esterase
references: Blood. 2009 Apr 16;113(16):3655-65
references: 19221035
references: PLoS One. 2007 Dec 26;2(12):e1337
references: 18159231
references: PLoS One. 2013;8(3):e58621
references: 23554907
references: Nat Rev Cancer. 2007 Sep;7(9):684-700
references: 17721433
references: Nat Rev Drug Discov. 2011 Mar;10(3):221-37
references: 21358741
references: Leukemia. 2008 May;22(5):915-31
references: 18288131
references: Br J Haematol. 2011 Mar;152(5):524-42
references: 21314823
references: Cell Cycle. 2011 Sep 15;10(18):3168-75
references: 21897118
references: Leuk Res. 2010 Nov;34(11):1501-5
references: 20226526
references: Cancer J. 2010 Jan-Feb;16(1):1-9
references: 20164683
references: Cancer. 2010 May 1;116(9):2132-9
references: 20166215
references: Biochem Pharmacol. 2011 Nov 15;82(10):1457-66
references: 21664897
references: Hematol Oncol. 2012 Jun;30(2):89-97
references: 22674781
references: N Engl J Med. 2009 Sep 24;361(13):1235-48
references: 19776405
references: Leukemia. 2009 Oct;23(10):1933-5
references: 19494839
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Stem Cells Transl Med. 2013 Feb;2(2):143-50
references: 23349328
references: Nat Rev Drug Discov. 2010 Jun;9(6):447-64
references: 20467424
references: J Proteomics. 2012 Feb 2;75(4):1343-56
references: 22115753
references: Blood. 1996 Oct 15;88(8):2826-32
references: 8874178
references: J Clin Oncol. 2008 Jul 20;26(21):3645-6
references: 18640945
references: Nat Rev Clin Oncol. 2009 Sep;6(9):535-43
references: 19652654
references: Cancer Res. 1998 Jul 15;58(14):3163-72
references: 9679985
references: Methods Mol Biol. 2013;965:93-120
references: 23296653
references: Blood. 1997 Dec 1;90(11):4384-93
references: 9373249
references: Cancer Res. 2007 Jul 1;67(13):6253-62
references: 17616683
references: J Clin Oncol. 2011 Feb 10;29(5):487-94
references: 21220605
references: Cell Cycle. 2012 Nov 1;11(21):4079-92
references: 23095522
references: Blood. 2007 Aug 1;110(3):1079-80
references: 17644748
references: Leukemia. 2010 Oct;24(10):1779-81
references: 20811401
references: Leukemia. 2010 Mar;24(3):663-5
references: 20033056
references: Anticancer Drugs. 2011 Feb;22(2):158-65
references: 20948428
references: Cell Death Differ. 2012 Jan;19(1):107-20
references: 21760595
references: Blood. 1990 Dec 15;76(12):2483-92
references: 1702327
references: Cell Rep. 2012 Aug 30;2(2):257-69
references: 22854025
references: Clin Cancer Res. 2013 Jan 15;19(2):380-92
references: 23213056
references: Eur J Cancer. 2012 Nov;48(17):3257-66
references: 22770878
references: Am J Hematol. 2013 Apr;88(4):318-27
references: 23526416
references: Oncogene. 2013 Sep 12;32(37):4331-42
references: 23085751
references: Int J Hematol. 2012 Aug;96(2):186-93
references: 22791510
references: Blood. 2005 Oct 15;106(8):2841-8
references: 15998836
references: Cell Cycle. 2013 Feb 1;12(3):417-21
references: 23287530
references: Curr Opin Oncol. 2012 Nov;24(6):711-9
references: 23014187
references: Leuk Res. 2010 May;34(5):553-65
references: 19811822
references: Int J Cancer. 1980 Feb 15;25(2):213-8
references: 6156128
references: Leukemia. 2012 Jun;26(6):1180-8
references: 22182854
references: Biochem Pharmacol. 2008 Dec 1;76(11):1417-25
references: 18617157
references: Blood. 2008 Feb 15;111(4):2170-80
references: 17925489
references: Oncogene. 2009 Jun 4;28(22):2205-18
references: 19398952
references: Methods Mol Biol. 2007;371:21-31
references: 17634571
references: Exp Cell Res. 2011 Jan 1;317(1):117-30
references: 20804750
references: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3081-90
references: 18065491
references: Cell Cycle. 2013 Jan 1;12(1):183-90
references: 23255111
references: Eur J Haematol. 2008 Nov;81(5):344-53
references: 18637032
references: Nat Chem Biol. 2010 Mar;6(3):166-169
references: 20154661
references: Nat Genet. 2004 Mar;36(3):257-63
references: 14770183
references: Blood. 2013 Mar 21;121(12):2264-73
references: 23325840
references: Cell Death Differ. 2009 Aug;16(8):1093-107
references: 19373242
references: J Clin Oncol. 2005 Sep 10;23(26):6285-95
references: 16155011
references: PLoS One. 2011;6(12):e29014
references: 22216158
references: Curr Opin Hematol. 2009 Mar;16(2):84-91
references: 19468269
references: Cell Death Differ. 2009 Jan;16(1):3-11
references: 18846107
references: Prog Clin Biol Res. 1986;226:215-33
references: 3543956
references: J Anat. 1993 Aug;183 ( Pt 1):97-101
references: 8270480